Another example of acquire resistance to ICIs was described by Gettinger et al. who demonstrated a complete genomic loss of B2M (a copy number variation) in lung cancer lesions after anti-PD-L1 and anti-CTLA-4 treatment [20]. The gene discussed is B2M; the disease is lung carcinoma.